Teleflex (NYSE:TFX - Get Free Report) had its price objective decreased by analysts at Morgan Stanley from $191.00 to $173.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the medical technology company's stock. Morgan Stanley's price target points to a potential upside of 37.92% from the stock's previous close.
Several other research firms also recently issued reports on TFX. Wells Fargo & Company decreased their price target on Teleflex from $146.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday. Needham & Company LLC reiterated a "hold" rating on shares of Teleflex in a report on Wednesday, March 12th. Truist Financial dropped their price target on shares of Teleflex from $149.00 to $140.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Royal Bank of Canada lowered their target price on shares of Teleflex from $150.00 to $145.00 and set a "sector perform" rating on the stock in a research note on Friday. Finally, Piper Sandler reissued a "neutral" rating and set a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $165.00.
Get Our Latest Report on TFX
Teleflex Stock Down 0.8 %
Shares of NYSE TFX traded down $0.98 during trading hours on Monday, hitting $125.44. The stock had a trading volume of 49,306 shares, compared to its average volume of 635,983. The firm's 50-day moving average price is $135.82 and its two-hundred day moving average price is $169.89. Teleflex has a 52 week low of $124.57 and a 52 week high of $249.91. The company has a market capitalization of $5.82 billion, a P/E ratio of 24.97, a P/E/G ratio of 1.73 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42.
Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.88 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $700.67 million for the quarter, compared to analyst estimates of $699.37 million. During the same quarter in the prior year, the business posted $3.21 EPS. Teleflex's quarterly revenue was down 5.0% on a year-over-year basis. Analysts anticipate that Teleflex will post 13.98 EPS for the current fiscal year.
Hedge Funds Weigh In On Teleflex
Several institutional investors and hedge funds have recently added to or reduced their stakes in TFX. Headlands Technologies LLC acquired a new stake in shares of Teleflex during the 4th quarter worth approximately $29,000. MassMutual Private Wealth & Trust FSB lifted its position in Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock worth $27,000 after purchasing an additional 100 shares during the period. Whipplewood Advisors LLC boosted its stake in Teleflex by 7,700.0% during the first quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock worth $32,000 after buying an additional 231 shares in the last quarter. Allworth Financial LP increased its holdings in Teleflex by 504.8% in the 1st quarter. Allworth Financial LP now owns 254 shares of the medical technology company's stock valued at $34,000 after buying an additional 212 shares during the period. Finally, True Wealth Design LLC raised its stake in shares of Teleflex by 62.3% in the 4th quarter. True Wealth Design LLC now owns 271 shares of the medical technology company's stock valued at $48,000 after buying an additional 104 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors.
About Teleflex
(
Get Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
